Novartis meningitis B vaccine Bexsero® receives FDA Breakthrough Therapy designation in the US

The designation highlights the potential of Bexsero to meet the urgent need for a licensed vaccine in the US against unpredictable and devastating meningitis B Bexsero, already approved in Europe, Canada and Australia, is the only broad coverage meningitis B vaccine that can be used from two months of age Bexsero was recently provided to two US universities under an …

Novartis Receives Australian Approval for Bexsero

Novartis Bexsero® meningitis B vaccine receives clinical recommendation for use in infants and adolescents in Australia March 13, 2014 Novartis has announced that Australia has joined the growing number of countries where following licensure, Bexsero® (Meningococcal Group B Vaccine [rDNA, component, adsorbed]) has received a clinical recommendation for the vaccine’s routine use to help protect against meningitis B. These recommendations follow recent access milestones for Bexsero in multiple …